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Abstract 
Despite the recent progress in interferon (IFN) therapies for chronic hepatitis C, liver 
cirrhosis remains refractory. One of the major obstacles to successful IFN therapy is low 
platelet count. Currently, splenic interventions, such as partial splenic embolization (PSE) 
or surgical splenectomy, have been applied effectively and make standard IFN therapy 
possible. However, there may be a group of patients with low platelet counts who can be 
treated without splenic intervention. We here report two patients with advanced type C 
liver cirrhosis who were successfully treated using very-low-dose pegylated interferon 
α2a plus ribavirin. One patient had a very low platelet count (2.5 × 104/μl) due to 
splenomegaly before treatment. However, pretreatment serum HCV titers were low in 
both patients and early viral responses were obtained in both. Because PSE or 
splenectomy may still have some safety concerns, this attenuated IFN treatment protocol 
can be an alternative therapeutic option for patients with advanced type C liver disease, 
but good virological factors for sustained virological response.  
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Introduction 
Recent progress in the treatment of chronic hepatitis C has been outstanding [1–4]. 
Pegylated interferon α (PEG-IFN) was developed in order to ensure sustained exposure 
with once-weekly dosing and offers improved convenience with a better adverse effects 
profile. Ribavirin accelerates clearance of virus by IFN and improves treatment outcomes. 
PEG-IFN plus ribavirin treatment can currently achieve sustained virological response 
(SVR) even in about 50% of refractory patients with genotype 1b and high viral titers  
[2–4]. However, the SVR rate for PEG-IFN plus ribavirin treatment remains low in 
patients with liver cirrhosis [5–8]. In addition, a high rate of severe adverse effects is seen, 
and discontinuation of treatment reportedly occurs in about 10–25% of patients [5–7]. 
There is thus a conflict between the high risk of hepatocarcinogenesis and liver failure, 
which are urgent indications for therapy, and low therapeutic outcome. 
 One of the major obstacles to therapy in patients with type C hepatic cirrhosis are the 
low platelet counts which IFN treatment inevitably lowers further. Partial splenic 
embolization (PSE) has recently become more commonly applied to increase platelet 
counts and make standard IFN treatment feasible [9–15], and there has been much 
progress in the procedure, ensuring that it can be performed safely [9–13]. However, 
because of the level of skill required, it cannot be performed with equal safety in every 
facility. In addition, certain risks of severe complications remain [9, 14, 15]. Thus there is 
an urgent need for a new IFN protocol for the specific subgroup of patients that can 
possibly avoid the use of medical or surgical splenic intervention. 
We performed such an attenuated protocol in two advanced liver cirrhosis patients, 
one with thrombocytopenia and one with neutropenia. We achieved SVR due to low 
HCV titers before treatment, and the rapid decrease in HCV titers after start of the 
therapy supported the continuation and completion of treatment.  
Patient 1 
A 61-year-old man had been followed in the outpatient clinic of Niigata University from 2003 with 
a diagnosis of type C liver cirrhosis. Ascites was identified in 2005, but was resolved with diuretics. 
Clinical data as of November 2007 are shown in table 1. He had low serum albumin levels. Thrombo- 
and leucocytopenia due to splenomegaly were also observed. Gastrointestinal fiberscopy showed a mild 
esophageal varix. HCV markers showed group 1 and a low titer (36 kIU/ml) according to qualitative 
Amplicore HCV Test, v.2.0. (Roche Molecular Systems, Branchburg, N.J., USA). A very low platelet 
count (2.5 × 10
4/μl) prevented regular-dose-based IFN therapy. Considering the possibility of severe 
side effects of PSE or surgical splenectomy, very low doses of PEG-IFNα2a (Pegasys; 30 μg = 1/3 of 90 μg 
vial, Roche Laboratories, Nutley, N.J., USA) were started after obtaining informed consent, particularly 
regarding the risks of hemorrhagic side effects. This dose of IFN was administered with an interval of 
10–14 days (total 23 times, total dose 690 μg), and platelet count did not reach <2.5 × 10
4/μl. HCV RNA 
became negative (quantitative Amplicor Test, Roche Molecular systems) at 4 weeks after starting IFN, 
and then ribavirin (600 mg/day; Copegus, Roche Laboratories) was initiated. Laboratory data after the 
start of therapy are shown in figure 1. Therapy (9 months in total) was continued until computed 
tomography revealed a solitary HCC (S7, 13 mm). HCV RNA remained negative both during therapy 
and 24 weeks after the end of treatment, thus confirming SVR. HCC was successfully ablated by 
radiofrequency ablation and no recurrence has been identified to date (March 2010). 
Patient 2 
A 67-year-old woman had been followed in the outpatient clinic of Niigata University since 1998 
with a diagnosis of type C liver cirrhosis. Surgical resection of HCC (S3, 20 mm) was performed in 2003 
and ascites were treated using diuretics in 2006. She was very interested in the progress of treatment for  
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hepatitis C, particularly with regard to PEG-IFN, and she requested therapy. As she had a low titer of 
HCV (110 kIU/ml), we started IFN therapy from September 2007 with a dose of 90 μg PEG-IFNα2a 
(Pegasys). As neutrophil count fell to <750/μl the following week, the dose was reduced to 45 μg and 
then to 30 μg in November. Serum HCV RNA decreased to <5 kIU/ml at 4 weeks and became negative 
8 weeks after starting IFN. Ribavirin (Copegus, 200 mg/day) was added from November to facilitate 
viral clearance. Weekly treatment with PEG-IFN (11 months in total) was continued (total dose 
1,475 μg) until computed tomography revealed a solitary HCC (S7, 10 mm). The HCC was successfully 
ablated using radiofrequency ablation and no recurrences have yet been identified (March 2010). HCV 
RNA remained negative both during therapy and 24 weeks after the end of treatment, thus indicating 
SVR. 
Discussion 
We present two patients with advanced liver cirrhosis due to HCV who were 
successfully treated with very-low-dose administration of PEG-IFNα2a plus ribavirin. 
The main reason we decided to treat these patients was the low titer of HCV, which is a 
good viral condition for obtaining SVR [1].  
Patient 1 had severe thrombocytopenia due to splenomegaly. The pretreatment platelet 
count (2.5 × 10
4/μl) was even below the standard level for discontinuation of PEG-IFN 
plus ribavirin (5.0 × 10
4/μl). Currently, PSE or surgical resection is typically performed in 
order to raise the platelet counts, then enabling standard IFN therapy [9–13]. The 
increase in platelet counts after PSE may also improve the SVR rate in chronic hepatitis C 
patients with thrombocytopenia [11–13]. However, this procedure is associated with 
serious complications, such as splenic abscess, that are potentially life-threatening 
[14, 15]. It should also be noted that the long-term effects of PSE and surgical 
splenectomy remain unknown [10]. We therefore selected a very low dose of PEG-IFN 
rather than splenic intervention, after obtaining careful informed consent from the 
patient. Fortunately, platelet count did not decrease significantly during treatment, and 
the treatment was well tolerated without any significant side effects.  
Even with the recent progress of predicting IFN treatment outcome, it remains difficult 
to perfectly predict SVR [16]. The response-guided concept is thus predominant [2–4]. 
Virus decrease during IFN treatment can give patients motivation to adhere to therapy, 
while discontinuation of therapy to avoid a handful of adverse effects and therapeutic 
costs is possible when negative predictive value is high. Currently, early viral response 
(negative HCV RNA after 12 weeks of therapy) is the most commonly used marker to 
determine the outcome of IFN therapy [17]. Fortunately, HCV RNA in the sera became 
negative shortly after the start of treatment (4 weeks in the patient 1 and 8 weeks in 
patient 2). These good responses enabled the continuation of treatment and predicted the 
possible achievement of SVR. In other words, discontinuation of treatment should always 
be considered if viral decrease is insufficient. Initially, we did not administer ribavirin, 
deciding instead to monitor viral response to PEG-IFN, but we added ribavirin after a 
good viral response was obtained, and this might have accelerated viral clearance in the 
patients. We administered PEG-IFNα2a, which is normally used weekly, with a 10- to 
14-day interval in patient 1. As PEG-IFNα2a has a longer half life than PEG-IFNα2b [18], 
significant effects were seen, despite the longer interval between doses.  
Unfortunately, both patients developed complicating HCC. It remains uncertain 
whether the SVR obtained in the patients will benefit their prognosis. HCC too small to 
be visualized on imaging might have been present at the start of IFN treatment. If the 
primary goal of IFN treatment is the prevention of HCC occurrence, this was not 
achieved in either patient. However, SVR after HCC ablation is reported to improve  
Case Rep Gastroenterol 2010;4:261–266 
DOI: 10.1159/000318742 
Published online: July 28, 2010  © 2010 S. Karger AG, Basel 
ISSN 1662–0631 
www.karger.com/crg 
 
 
264
prognosis in patients with HCC associated with hepatitis C [19–22]. Moreover, viral 
eradication suppresses the hepatic inflammation, lowers ALT levels and maintains hepatic 
reserve function. To date (March 2010), both patients have been free from HCC 
recurrence and quality of life has remained satisfactory. 
In conclusion, an attenuated PEG-IFN protocol for patients with good viral parameters 
for SVR without splenic intervention should be the subject of a clinical trial in order to 
determine the cost-benefit balance between the risk of splenic intervention, prediction of 
IFN therapy outcome, and adverse effects, finally examining whether there are actual 
long-term clinical benefits. Careful and strict monitoring of both the antiviral effects and 
the appearance of severe adverse effects is absolutely necessary. 
 
 
 
Table 1. Laboratory data at the start of PEG-IFNα2a therapy 
Patient 1      
WBC 1,700/μl  TP  7.0  g/dl 
Neutro 71.1%  Alb  3.2  g/dl 
Eosino  2.4%  T.Bil  1.9 mg/dl (D 0.1, ID 1.8) 
Baso 0.6%  AST  67  IU/l 
Lympho 20.0%  ALT  70  IU/l 
Mono 5.9%  ALP  261  IU/l 
RBC  396 × 10
4/μl γ-GTP    55  IU/l 
Hb  10.8 g/dl  LDH  233 IU/l 
Plt  2.5 × 10
4/μl ChE  113  IU/l 
   BUN  16  mg/dl 
HBsAg –  Cr  0.6  mg/dl 
HCV RNA  36 kIU/ml  T.Chol   158 mg/dl 
HCV serogroup  1  FBS  82 mg/dl 
AFP 7.1  ng/dl     
Patient 2      
WBC 3,170/μl  TP  8.4  g/dl 
Neutro 24.0%  Alb  2.6  g/dl 
Eosino  2.5%  T.Bil  0.7 mg/dl (D 0.1, ID 0.6) 
Baso 0.3%  AST  39  IU/l 
Lympho 63.5%  ALT  67  IU/l 
Mono 9.7%  ALP  338  IU/l 
RBC  391 × 10
4/μl γ-GTP    17  IU/l 
Hb  10.1 g/dl  LDH  304 IU/l 
Plt  15.8 × 10
4/μl ChE  84  IU/l 
   BUN  15  mg/dl 
HBsAg –  Cr  0.6  mg/dl 
HCV RNA  110 kIU/ml  T.Chol   131 mg/dl 
HCV serogroup  1  FBS  88 mg/dl 
AFP 5  ng/dl     
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Fig. 1. Changes in laboratory data (ALT, WBC, platelets) for patients 1 and 2 after the start of 
PEG-IFNα2a. The vertical axis shows the values for ALT and WBC (left) and platelets (right). 
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